New sales setup will ensure success for Lundbeck's first new drug in years
Lundbeck will concentrate on one specific type of practitioner when the new drug eptinezumab is launched on the ever competitive migraine market. To ensure a strong launch, USA boss Peter Anastasiou is splitting his business in two.
With the expected approval of migraine treatment eptinezumab just three months away, Lundbeck's US organization is busy.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
